BiopharmaINSM

Insmed

Insmed is a biopharmaceutical company focused on serious and rare respiratory diseases, advancing the oral DPP1 inhibitor brensocatib across neutrophil-driven conditions such as bronchiectasis and chronic rhinosinusitis.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Insmed forecasting benchmarks

1 benchmark

ResolvedPhase 2b

BiRCh (brensocatib) Phase 2b for CRSsNP

Brensocatib · Chronic rhinosinusitis without nasal polyps

Dec 17, 2025Clinical Trials

Pipeline on the platform

Brensocatib· Oral reversible DPP1 inhibitor

Therapeutic areas

Chronic rhinosinusitis without nasal polyps· CRSsNP

About Insmed

What is Insmed developing?

Which Insmed trials can I forecast?

We track 1 Insmed trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes